Kratom is banned in some U.S. states because its active compounds bind to the same brain receptors as opioids, raising concerns about addiction, liver damage, and contaminated products reaching consumers without any quality controls. As of 2025, seven states have outright bans on kratom possession or distribution, with Louisiana being the most recent to join that list. But the legal picture is more complicated than a simple banned-or-legal divide, with some states choosing regulation over prohibition and even individual cities imposing local bans in otherwise legal states.
How Kratom Acts on the Brain
The core reason kratom draws regulatory scrutiny is pharmacological: its main active compound, mitragynine, is a partial agonist of the mu-opioid receptor, the same receptor targeted by morphine, heroin, and prescription painkillers. That means kratom can produce pain relief, sedation, and a sense of euphoria through the same basic pathway as traditional opioids, though its binding affinity is considerably weaker than morphine’s.
A second compound found in kratom, 7-hydroxymitragynine, is far more potent. Concentrated versions of this compound have alarmed public health experts because they can produce effects similar to heroin while being sold with little to no oversight. Reports of heavily concentrated 7-hydroxymitragynine products have been a major driver behind legislative action in several states, with users experiencing rapid heart rates, seizures, confusion, and respiratory depression.
Kratom also interacts with serotonin, dopamine, and norepinephrine systems in the brain, giving it a broader and less predictable pharmacological profile than a single-target drug. This complexity makes it harder for regulators to classify neatly and harder for consumers to predict how it will affect them.
The FDA’s Specific Health Warnings
The FDA has warned consumers not to use kratom, citing risks of liver toxicity, seizures, and substance use disorder. In rare cases, deaths have been confirmed by medical examiners or toxicology reports. Between 2015 and 2025, 233 kratom-associated deaths were reported, though 79% of those involved multiple substances, making it difficult to isolate kratom as the sole cause.
Addiction is one of the FDA’s central concerns. Cases of kratom-related substance use disorder follow a familiar pattern: people use more than intended, develop tolerance, experience cravings, and continue using despite negative consequences. When they stop, withdrawal symptoms set in. The FDA has also flagged cases of neonatal abstinence syndrome, where newborns showed withdrawal signs like jitteriness, irritability, and muscle stiffness after prolonged prenatal exposure.
Liver injury is another documented risk. In published case reports, patients have developed jaundice and significantly elevated liver enzymes within weeks of starting regular kratom use. One case in the Journal of Hepatology described a patient who developed cholestatic liver injury after just three weeks, with bilirubin levels nearly nine times the upper limit of normal. Once other causes like viral hepatitis and acetaminophen toxicity were ruled out, kratom was identified as the likely culprit.
Contamination in Unregulated Products
Because kratom is sold as a supplement or botanical product without pharmaceutical-grade manufacturing standards, contamination has been a persistent problem. The FDA tested 30 kratom products from various sources and found significant levels of lead and nickel exceeding safe daily exposure limits for oral intake. Some products contained staggering nickel concentrations. One product tested at 29,000 nanograms per gram of nickel, while several others showed lead levels well above detection thresholds.
The FDA concluded that heavy, long-term kratom users could develop heavy metal poisoning, potentially leading to nervous system damage, kidney damage, anemia, high blood pressure, or increased cancer risk. Separate incidents have also involved salmonella contamination in kratom products, prompting public health warnings. These contamination issues give legislators a concrete, non-controversial justification for either banning the substance or imposing strict manufacturing requirements.
Which States Have Bans and Restrictions
Seven states now have outright bans on kratom possession or distribution. Louisiana became the seventh in 2025. Meanwhile, Rhode Island moved in the opposite direction, reversing its previous ban by enacting a regulatory framework set to take effect in 2026.
In 2025 alone, six states (South Dakota, Rhode Island, Mississippi, South Carolina, Colorado, and Nebraska) enacted laws prohibiting the sale of kratom to anyone under 21. Over 100 kratom-related bills were introduced across nearly all 50 states during the 2024-2025 legislative session, with 13 ultimately enacted in various states. The legislative trend has been heavily active, reflecting how unsettled kratom policy remains.
Adding another layer of complexity, at least six otherwise kratom-legal states have cities or counties with local bans. Denver, for example, prohibits kratom for human consumption even though Colorado allows it statewide. San Diego, Sarasota County in Florida, and jurisdictions in Illinois, Mississippi, and New Hampshire have similar local restrictions. This means kratom can be perfectly legal in one town and carry fines or jail time in the next.
Regulation vs. Prohibition
The legislative divide comes down to two competing approaches. Some states view kratom as dangerous enough to ban entirely, pointing to opioid-like effects, addiction potential, documented liver injuries, and contaminated products. Others see a substance that millions of people use, often as an alternative to prescription painkillers, and prefer to regulate it rather than push it underground.
The regulatory approach is built around the Kratom Consumer Protection Act, a model law that has been adopted or adapted in multiple states. Its goals are to regulate the preparation, distribution, and sale of kratom products, prohibit the sale of adulterated or contaminated products, set age restrictions, require labeling standards, and establish fines for violations. States that pass versions of this act are essentially treating kratom more like alcohol or tobacco: legal but controlled.
Supporters of regulation argue that bans don’t eliminate demand; they just remove any quality oversight. When kratom is illegal, users still find it, but without any assurance that what they’re buying hasn’t been laced with concentrated synthetic compounds or contaminated with heavy metals. The contamination data from the FDA’s own testing, they argue, is actually evidence for regulation rather than prohibition.
Why the Federal Government Hasn’t Settled It
Kratom remains unscheduled at the federal level. The DEA considered classifying it as a Schedule I controlled substance in 2016 but withdrew the proposal after significant public backlash, including comments from researchers who argued that its partial opioid activity and lack of strong beta-arrestin recruitment (a cellular response associated with the most dangerous opioid side effects like respiratory depression) made it fundamentally different from drugs like heroin or fentanyl. The FDA continues to warn against kratom use but has not succeeded in getting it scheduled.
This federal ambiguity is precisely why the state-by-state patchwork exists. Without a clear federal classification, each state legislature weighs the same evidence and reaches different conclusions based on local politics, the influence of advocacy groups on both sides, and how heavily the opioid crisis has affected their communities. States hit hardest by opioid deaths tend to be more receptive to arguments that any opioid-receptor-active substance needs strict controls. States with strong libertarian or supplement-industry constituencies tend to favor consumer choice with guardrails.